Evidence map›Paper›PMID 29624843›Full record

ArticleLiver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society2018

A novel multimarker assay for the phenotypic profiling of circulating tumor cells in hepatocellular carcinoma.

Colin M Court, Shuang Hou, Paul Winograd, Nicholas H Segel, Qingyu Wilda Li, Yazhen Zhu, Saeed Sadeghi, Richard S Finn, Ekambaram Ganapathy, Min Song and 8 more

Open access · bronzeAbstract readEvaluation Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
57citing papers in PubMed, 1 pooled it
3.3field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

57 citing papers in PubMed, 1 synthesis or guideline pooled it, 74 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Microvascular Invasion in Hepatocellular Carcinoma: Some Puzzling Facets.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2024
    Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Review
  19. Circulating tumour cell isolation, analysis and clinical application.Cellular oncology (Dordrecht, Netherlands) · 2023
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 2 institutions in 1 country.

Colin M CourtDepartments of Surgery, University of California, Los Angeles, Los Angeles, CA.ORCID 0000-0002-9357-8957
Shuang HouDepartments of Surgery, University of California, Los Angeles, Los Angeles, CA.
Paul WinogradDepartments of Surgery, University of California, Los Angeles, Los Angeles, CA.
Nicholas H SegelDepartments of Surgery, University of California, Los Angeles, Los Angeles, CA.
Qingyu Wilda LiDepartments of Surgery, University of California, Los Angeles, Los Angeles, CA.
Yazhen ZhuDepartment of Molecular and Medical Pharmacology, University of California, Los Angeles, Los Angeles, CA.
Saeed SadeghiDepartment of Medicine, Division of Hematology/Oncology, University of California, Los Angeles, Los Angeles, CA.
Richard S FinnDepartment of Medicine, Division of Hematology/Oncology, University of California, Los Angeles, Los Angeles, CA.
Ekambaram GanapathyDepartment of Pathology and Laboratory Medicine, University of California, Los Angeles, Los Angeles, CA.
Min SongDepartment of Molecular and Medical Pharmacology, University of California, Los Angeles, Los Angeles, CA.
Samuel W FrenchDepartment of Pathology and Laboratory Medicine, University of California, Los Angeles, Los Angeles, CA.
Bita V NainiDepartment of Pathology and Laboratory Medicine, University of California, Los Angeles, Los Angeles, CA.
Shonan ShoDepartments of Surgery, University of California, Los Angeles, Los Angeles, CA.
Fady M KaldasDepartments of Surgery, University of California, Los Angeles, Los Angeles, CA.
Ronald W BusuttilDepartments of Surgery, University of California, Los Angeles, Los Angeles, CA.
James S TomlinsonDepartments of Surgery, University of California, Los Angeles, Los Angeles, CA.
Hsian-Rong TsengDepartment of Molecular and Medical Pharmacology, University of California, Los Angeles, Los Angeles, CA.
Vatche G AgopianDepartments of Surgery, University of California, Los Angeles, Los Angeles, CA.
University of California, Los Angeles · USCalifornia NanoSystems Institute · US

Funding

Women's CancersP30CA016042 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Samuel Wheeler French · 1985 to 2026
$134.5M
Integrated analysis of HCC CTCs for Liver Transplant Candidate SelectionR01CA246304 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI AGOPIAN, VATCHE, TSENG, HSIAN-RONG · 2020 to 2024
$2.8M
Thermoresponsive NanoVelcro CTC Purification System for Prostate Cancer ProfilingU01CA198900 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI POSADAS, EDWIN MELENCIO, TSENG, HSIAN-RONG · 2015 to 2019
$2.4M
CTC Purification System Based on Thermoresponsive NanoSubstratesR44CA180482 · NCI · CYTOLUMINA TECHNOLOGIES CORPORATION, INC · PI LIU, SEAN XIAO, TSENG, HSIAN-RONG · 2015 to 2016
$2.0M
Molecular and Functional Analysis of Single Circulating Melanoma CellsR33CA174562 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI TSENG, HSIAN-RONG · 2013 to 2015
$987k
Analysis of HCC CTC Phenotype for Liver Transplant Candidate SelectionR21CA216807 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI AGOPIAN, VATCHE · 2018 to 2019
$368k
NCI NIH HHS P30 CA016042NCI NIH HHS R01 CA246304NCI NIH HHS R21 CA216807NCI NIH HHS R33 CA174562NCI NIH HHS R44 CA180482NCI NIH HHS U01 CA198900
6 · The paper itself

Abstract

Current clinicopathologic staging systems and serum biomarkers poorly discriminate tumor biology in hepatocellular carcinoma (HCC), with high recurrence rates following curative-intent surgical resection and liver transplantation (LT). Identification of accurate biomarkers for improved prognostication and treatment selection is a critical unmet need. We sought to develop a novel "liquid-biopsy" assay capable of detecting HCC circulating tumor cells (CTCs) and characterizing phenotypic subpopulations with prognostic significance. Using HCC cell lines, a tissue microarray, and human blood samples, an antibody cocktail targeting the cell-surface markers asialoglycoprotein receptor (ASGPR), glypican-3, and epithelial cell adhesion molecule was optimized for HCC CTC capture using the NanoVelcro CTC Assay. The ability of HCC CTCs and vimentin (VIM)-positive CTCs (a subpopulation expressing an epithelial-to-mesenchymal phenotype) to accurately discriminate tumor stage, recurrence, progression, and overall survival (OS) was evaluated in a prospective study of 80 patients. Multimarker capture detected greater numbers of CTCs than any individual antibody alone for both cell line and patient samples (P < 0.001). HCC CTCs were identified in 59/61 (97%) patients, and HCC (median, 6 CTCs) and non-HCC patients (median, 1 CTC; area under the receiver operating characteristic curve [AUROC] = 0.92; P < 0.001; sensitivity = 84.2%; specificity = 88.5%) were accurately discriminated. VIM-positive CTCs accurately discriminated early-stage, LT eligible patients (median, 0 CTCs) from locally advanced/metastatic, LT ineligible patients (median, 6 CTCs; AUROC = 0.89; P = 0.001; sensitivity = 87.1%; specificity = 90.0%), and predicted OS for all patients (hazard ratio [HR], 2.21; P = 0.001), and faster recurrence after curative-intent surgical or locoregional therapy in potentially curable early-stage HCC (HR, 3.14; P = 0.002). In conclusion, we developed a novel multimarker CTC enrichment assay that detects HCC CTCs with high efficiency and accuracy. A phenotypic subpopulation of VIM-positive CTCs appears to signify the presence of aggressive underlying disease and occult metastases and may have important implications for treatment selection. Liver Transplantation 24 946-960 2018 AASLD.

Indexed as

AgedAsialoglycoprotein ReceptorBiological AssayBiomarkers, TumorCarcinoma, HepatocellularCell Line, TumorEpithelial Cell Adhesion MoleculeFemaleGlypicansHealthy VolunteersHumansImmunoassayKaplan-Meier EstimateLiquid BiopsyLiver CirrhosisLiver NeoplasmsAsialoglycoprotein ReceptorBiomarkers, TumorEpithelial Cell Adhesion MoleculeGlypicansGPC3 protein, humanVimentinVIM protein, human

Identifiers

PMID29624843
PMCPMC6097911
OpenAlexW2796321767

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.